Hudson Bay Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Hudson Bay Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-78,934	Closed	-$15.7M	–	1192
2025 Q3	$15.7M	Buy	+78,934	New	+$14.7M	0.05%	267
2018 Q1	–	Sell	-120,000	Closed	-$4.81M	–	765
2017 Q4	$4.81M	Hold	120,000	–	–	0.1%	168
2017 Q3	$4.35M	Buy	120,000 +45,000	+60%	+$1.29M	0.11%	162
2017 Q2	$2.08M	Buy	+75,000	New	+$1.98M	0.04%	332

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Hudson Bay Capital Management's ASND Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 78,934 shares — an estimated $15.7M sold.

Hudson Bay Capital Management first reported a position in ASND in Q2 2017 and held it in 4 quarters. The position peaked at $15.7M in Q3 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Hudson Bay Capital Management reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 78,934 Ascendis Pharma A/S shares in Q4 2025, an estimated $15.7M.
Hudson Bay Capital Management first reported a position in Ascendis Pharma A/S in Q2 2017 and held it in 4 quarters.
Hudson Bay Capital Management's Ascendis Pharma A/S position peaked at $15.7M in Q3 2025.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.